论文部分内容阅读
将60例糖尿病性肾病Ⅲ、Ⅳ期患者随机分为3组:凯时组、凯时+缬沙坦组、凯时+缬沙坦+舒洛地特组。凯时组每日给予前列腺素E110μg治疗20天,凯时+缬沙坦组每日给予前列腺素E110μg、缬沙坦80mg治疗20天,凯时+缬沙坦+舒洛地特组每日给予前列腺素E110μg、缬沙坦80mg、舒洛地特60mg治疗20天,治疗前后分别测定尿白蛋白排泄率和尿白蛋白/肌酐比值变化。结果:治疗前后,3组患者的尿白蛋白排泄率和尿白蛋白/肌酐比值较前明显下降(P<0.05)。与凯时+缬沙坦组相比,凯时+缬沙坦+舒洛地特组改善更明显(P<0.05),无不良药物反应。结论:临床使用前列腺素E1、缬沙坦联合舒洛地特治疗糖尿病性肾病Ⅲ、Ⅳ期患者安全有效。
Sixty diabetic patients with stage Ⅲ and Ⅳ diabetic nephropathy were randomly divided into three groups: Kay, Kay + valsartan group, Kay + valsartan + sulodexide group. Kai-hour group given prostaglandin E110μg daily treatment for 20 days, Kay hours + valsartan group daily prostaglandin E110μg, valsartan 80mg for 20 days, Kay + Valsartan + sulodexide group daily Prostaglandin E110μg, valsartan 80mg, sulodexide 60mg for 20 days, before and after treatment were measured urinary albumin excretion and urinary albumin / creatinine ratio changes. Results: Before and after treatment, urinary albumin excretion rate and urinary albumin / creatinine ratio decreased significantly in the three groups (P <0.05). Compared with Kaishi + valsartan group, Kaishi + valsartan + sulodexide group improved more obviously (P <0.05), and no adverse drug reaction. Conclusion: The clinical use of prostaglandin E1, valsartan combined with sulodexide in patients with stage Ⅲ, Ⅳ diabetic nephropathy is safe and effective.